Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models.

The clinical implication of the current findings is quite significant: with neoadjuvant G47Δ therapy, the resection area of the tongue tumor can be kept to a minimum, not requiring, e.g., subtotal resection with free flap reconstruction, thereby preserving patients’ speech and swallowing functions and QOL. 45 , 46 Furthermore, neoadjuvant G47Δ therapy confers on tongue cancer patients the possibility of a long-term survival regardless of the extent of resection margins.

also in 5,695 other papers